Alnylam Pharmaceuticals annual operating expenses
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Operating Expenses Growth & History (ALNY)
Alnylam Pharmaceuticals's operating expenses was $2.54B for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.54B | $416.6M | +19.66% |
| 2024 | 2024-12-31 | $2.12B | $276.4M | +15.00% |
| 2023 | 2023-12-31 | $1.84B | $159.9M | +9.51% |
| 2022 | 2022-12-31 | $1.68B | $244.4M | +17.00% |
| 2021 | 2021-12-31 | $1.44B | $190.8M | +15.30% |
| 2020 | 2020-12-31 | $1.25B | $113.0M | +9.96% |
| 2019 | 2019-12-31 | $1.13B | $246.3M | +27.75% |
| 2018 | 2018-12-31 | $887.8M | $297.8M | +50.47% |
| 2017 | 2017-12-31 | $590.0M | $118.3M | +25.07% |
| 2016 | 2016-12-31 | $471.7M | $134.6M | +39.94% |
| 2015 | 2015-12-31 | $337.1M | −$118.4M | −26.00% |
| 2014 | 2014-12-31 | $455.5M | $315.4M | +225.13% |
| 2013 | 2013-12-31 | $140.1M | −$56.1M | −28.58% |
| 2012 | 2012-12-31 | $196.2M | $58.6M | +42.60% |
| 2011 | 2011-12-31 | $137.6M | −$6.5M | −4.54% |
| 2010 | 2010-12-31 | $144.1M | −$4.5M | −3.05% |
| 2009 | 2009-12-31 | $148.6M | $24.6M | +19.88% |
| 2008 | 2008-12-31 | $124.0M | — | — |
Alnylam Pharmaceuticals quarterly operating expenses
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $761.2M | $113.4M | +17.50% |
| Q1 2026 | 2026-03-31 | $687.4M | $181.5M | +35.87% |
| Q4 2025 | 2025-12-31 | $697.6M | $101.9M | +17.11% |
| Q3 2025 | 2025-09-30 | $683.8M | $188.0M | +37.91% |
| Q2 2025 | 2025-06-30 | $647.9M | $103.9M | +19.10% |
| Q1 2025 | 2025-03-31 | $505.9M | $22.8M | +4.71% |
| Q4 2024 | 2024-12-31 | $595.7M | $111.5M | +23.04% |
| Q3 2024 | 2024-09-30 | $495.8M | $38.7M | +8.45% |
| Q2 2024 | 2024-06-30 | $543.9M | $70.7M | +14.94% |
| Q1 2024 | 2024-03-31 | $483.2M | $55.5M | +12.98% |
| Q4 2023 | 2023-12-31 | $484.1M | $6.7M | +1.40% |
| Q3 2023 | 2023-09-30 | $457.2M | −$28.6M | −5.90% |
| Q2 2023 | 2023-06-30 | $473.2M | $90.8M | +23.74% |
| Q1 2023 | 2023-03-31 | $427.7M | $91.1M | +27.08% |
| Q4 2022 | 2022-12-31 | $477.5M | $58.0M | +13.83% |
| Q3 2022 | 2022-09-30 | $485.8M | $144.6M | +42.38% |
| Q2 2022 | 2022-06-30 | $382.5M | $46.0M | +13.67% |
| Q1 2022 | 2022-03-31 | $336.5M | −$4.3M | −1.25% |
| Q4 2021 | 2021-12-31 | $419.5M | $61.7M | +17.24% |
| Q3 2021 | 2021-09-30 | $341.2M | $11.0M | +3.33% |
| Q2 2021 | 2021-06-30 | $336.5M | $51.9M | +18.24% |
| Q1 2021 | 2021-03-31 | $340.8M | $44.5M | +15.01% |
| Q4 2020 | 2020-12-31 | $357.8M | −$12.0M | −3.24% |
| Q3 2020 | 2020-09-30 | $330.2M | $49.1M | +17.46% |
| Q2 2020 | 2020-06-30 | $284.6M | $7.9M | +2.85% |
| Q1 2020 | 2020-03-31 | $296.3M | $77.6M | +35.48% |
| Q4 2019 | 2019-12-31 | $369.8M | $128.4M | +53.18% |
| Q3 2019 | 2019-09-30 | $281.1M | $24.7M | +9.61% |
| Q2 2019 | 2019-06-30 | $276.7M | $54.4M | +24.47% |
| Q1 2019 | 2019-03-31 | $218.7M | $49.4M | +29.20% |
| Q4 2018 | 2018-12-31 | $241.4M | $56.2M | +30.32% |
| Q3 2018 | 2018-09-30 | $256.5M | $113.6M | +79.49% |
| Q2 2018 | 2018-06-30 | $222.3M | $85.9M | +62.94% |
| Q1 2018 | 2018-03-31 | $169.3M | $43.8M | +34.93% |
| Q4 2017 | 2017-12-31 | $185.2M | $52.3M | +39.39% |
| Q3 2017 | 2017-09-30 | $142.9M | $22.6M | +18.76% |
| Q2 2017 | 2017-06-30 | $136.4M | $35.2M | +34.84% |
| Q1 2017 | 2017-03-31 | $125.5M | $8.1M | +6.90% |
| Q4 2016 | 2016-12-31 | $132.9M | $32.8M | +32.80% |
| Q3 2016 | 2016-09-30 | $120.3M | $35.7M | +42.14% |
| Q2 2016 | 2016-06-30 | $101.2M | $19.5M | +23.93% |
| Q1 2016 | 2016-03-31 | $117.4M | $46.6M | +65.88% |
| Q4 2015 | 2015-12-31 | $100.1M | $30.3M | +43.50% |
| Q3 2015 | 2015-09-30 | $84.7M | $28.5M | +50.71% |
| Q2 2015 | 2015-06-30 | $81.6M | $29.3M | +56.08% |
| Q1 2015 | 2015-03-31 | $70.8M | −$206.6M | −74.49% |
| Q4 2014 | 2014-12-31 | $69.7M | $29.3M | +72.44% |
| Q3 2014 | 2014-09-30 | $56.2M | $14.9M | +36.25% |
| Q2 2014 | 2014-06-30 | $52.3M | $22.3M | +74.34% |
| Q1 2014 | 2014-03-31 | $277.3M | $248.9M | +874.97% |
| Q4 2013 | 2013-12-31 | $40.4M | −$56.4M | −58.24% |
| Q3 2013 | 2013-09-30 | $41.2M | $6.3M | +18.10% |
| Q2 2013 | 2013-06-30 | $30.0M | −$3.0M | −8.96% |
| Q1 2013 | 2013-03-31 | $28.4M | −$3.0M | −9.64% |
| Q4 2012 | 2012-12-31 | $96.8M | $62.8M | +184.49% |
| Q3 2012 | 2012-09-30 | $34.9M | $1.7M | +5.05% |
| Q2 2012 | 2012-06-30 | $33.0M | −$781,000 | −2.32% |
| Q1 2012 | 2012-03-31 | $31.5M | −$5.1M | −13.93% |
| Q4 2011 | 2011-12-31 | $34.0M | $439,000 | +1.31% |
| Q3 2011 | 2011-09-30 | $33.2M | −$3.2M | −8.70% |
| Q2 2011 | 2011-06-30 | $33.7M | −$4.5M | −11.80% |
| Q1 2011 | 2011-03-31 | $36.6M | $703,000 | +1.96% |
| Q4 2010 | 2010-12-31 | $33.6M | — | — |
| Q3 2010 | 2010-09-30 | $36.4M | $2.5M | +7.37% |
| Q2 2010 | 2010-06-30 | $38.2M | −$8.8M | −18.65% |
| Q1 2010 | 2010-03-31 | $35.9M | — | — |
| Q3 2009 | 2009-09-30 | $33.9M | — | — |
| Q2 2009 | 2009-06-30 | $47.0M | — | — |
Alnylam Pharmaceuticals operating expenses trends
Over the last five fiscal years, Alnylam Pharmaceuticals's operating expenses increased from $1.25B to $2.54B, a change of $1.29B. The latest reported quarter, Q2 2026, shows $761.2M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗Community posts
Alnylam’s product sales jump 52% as it enlarges a pivotal heart-disease trial
Alnylam ($ALNY) reported third-quarter 2026 product revenue of $1.29 billion, up 52%, led by Amvuttra and Onpattro’s combined $1.15 billion contribution. Total revenue increased a slower 17% to $1.46 billion because collaboration revenue de ...
